MARKET

ATXS

ATXS

Astria Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.53
-0.14
-1.45%
After Hours: 9.42 -0.11 -1.15% 17:49 09/27 EDT
OPEN
9.74
PREV CLOSE
9.67
HIGH
9.89
LOW
9.53
VOLUME
36.96K
TURNOVER
--
52 WEEK HIGH
47.82
52 WEEK LOW
6.31
MARKET CAP
122.22M
P/E (TTM)
-0.1673
1D
5D
1M
3M
1Y
5Y
--Oppenheimer Raises Astria Therapeutics' PT to $30 from $5 After 1 for 6 Reverse Stock Split, Keeps Outperform Rating
MT Newswires · 3d ago
Astria Therapeutics to Present at Upcoming Investor Conferences
BOSTON, September 10, 2021--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corpo...
Business Wire · 09/10 12:00
Catabasis Renames As Astria Therapeutics With New Disease Focus
Benzinga · 09/08 18:37
Catabasis Pharmaceuticals changes name to Astria Therapeutics
Catabasis Pharmaceuticals (CATB -3.0%) announces its new name, Astria Therapeutics. The name Astria originates from the Greek word for star, reflecting the company’s commitment to having patients serve as guiding stars.
Seekingalpha · 09/08 14:07
BRIEF-Catabasis Pharmaceuticals Renames To Astria Therapeutics
reuters.com · 09/08 12:32
Catabasis Pharmaceuticals Announces New Company Name, Astria Therapeutics, Highlighting New Company Focus
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced its new name, Astria Therapeutics, Inc.
Benzinga · 09/08 12:05
Do Institutions Own Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) Shares?
The big shareholder groups in Catabasis Pharmaceuticals, Inc. ( NASDAQ:CATB ) have power over the company. Large...
Simply Wall St. · 09/02 11:34
Wedbush Initiates Coverage On Catabasis Pharmaceuticals with Outperform Rating, Announces Price Target of $16
Wedbush analyst Laura Chico initiates coverage on Catabasis Pharmaceuticals (NASDAQ:CATB) with a Outperform rating and announces Price Target of $16.
Benzinga · 09/02 11:07
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATXS. Analyze the recent business situations of Astria Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ATXS stock price target is 23.75 with a high estimate of 36.00 and a low estimate of 13.00.
EPS
Institutional Holdings
Institutions: 73
Institutional Holdings: 9.53M
% Owned: 74.31%
Shares Outstanding: 12.82M
TypeInstitutionsShares
Increased
12
2.09M
New
17
3.58M
Decreased
23
426.70K
Sold Out
20
291.86K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.10%
Pharmaceuticals & Medical Research
-0.86%
Key Executives
Non-Executive Chairman/Independent Director
Kenneth Bate
President/Chief Executive Officer/Co-Founder/Director
Jill Milne
Chief Financial Officer
Noah Clauser
Chief Scientific Officer
Andrew Nichols
General Counsel
Benjamin Harshbarger
Other
Andrew Komjathy
Director
Jonathan Violin
Independent Director
Joanne Beck
Independent Director
Fred Callori
Independent Director
Hugh Cole
Independent Director
Michael Kishbauch
Independent Director
Gregg Lapointe
No Data
About ATXS
Astria Therapeutics, Inc., formerly Catabasis Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is focused on developing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is in preclinical development for the treatment of hereditary angioedema (HAE). HAE is a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen and airway. STAR-0215 is a monoclonal antibody inhibitor of plasma kallikrein, which is designed to provide long-acting attack prevention for HAE.

Webull offers kinds of Astria Therapeutics Inc stock information, including NASDAQ:ATXS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATXS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATXS stock methods without spending real money on the virtual paper trading platform.